• The rapid growth of antimicrobial resistance (AMR) is staggering, particularly when considering the slow rate at which new antibiotics are being developed and made available to patients 
  • International health authorities, including the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), continue to sound the alarm to promote increased preparedness, save human lives and avoid a heavy financial burden on healthcare systems2,3 
  • Debiopharm is one of the main sponsors and panel participants of the 2023 World Antimicrobial Resistance (World AMR) Congress in Philadelphia, Pennsylvania — a conference gathering key AMR stakeholders including international government agencies, policy associations, and healthcare industry professionals 

 

Debiopharm, a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.

 

Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*

 

“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm“We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”



“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.

 

Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.

 

World AMR 2022 Session Details

 

Session 1

 

Sept.7th, 08:35 EST
Keynote panel: How can we push AMR to the forefront of preparedness?

Morgane Vanbiervliet
Market Intelligence & Business Development Manager, Infectious Diseases
Debiopharm

+ other invited speakers

 

Session 2

 

Sept.7th, 11:00 – 11:30 EST

Antibiotic Development stream – Panel Discussion
The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement

Moderator:
Dr. Ricardo Chaves
Executive Medical Director
Debiopharm

Speaker:
Dr.L. Clifford McDonald,
Associate Director for Science in the Division of Healthcare Quality Promotion, CDC

 

Source: Debiopharm

 

References

[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.

[2] Antimicrobial resistance surveillance in Europe 2023–2021 data. www.who.int/europe/publications/i/item/9789289058537
[3] CDC Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[4] COVID-19 U.S. Impact on Antimicrobial Resistance. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf

«« Corticosteroids in Severe CAP


Atrial Fibrillation in the ICU »»



Latest Articles

Debiopharm, International Health Organisations, Anti-Microbial Resistance,2023 World Amr Congress The rapid growth of antimicrobial resistance (AMR) is staggering, particularly when considering the slow rate at which new antibiotics are being develope...